A Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Evaluate the Effect of APL180 on Endothelial Function in Patients With Familial Hypercholesterolemia

Trial Profile

A Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Evaluate the Effect of APL180 on Endothelial Function in Patients With Familial Hypercholesterolemia

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs APL 180 (Primary)
  • Indications Hyperlipoproteinaemia type II
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharma
  • Most Recent Events

    • 04 Nov 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 27 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top